Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.

@article{Narita2015CosteffectivenessAO,
  title={Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.},
  author={Yusuke Narita and Yukiko Matsushima and Takeru Shiroiwa and Koji Chiba and Yoichi Nakanishi and Tatsuo Kurokawa and Hisashi Urushihara},
  journal={Lung cancer},
  year={2015},
  volume={90 1},
  pages={71-7}
}
OBJECTIVES The combination use of gefitinib and epidermal growth factor receptor (EGFR) testing is a standard first-line therapy for patients with non-small cell lung cancer (NSCLC). Here, we examined the cost-effectiveness of this approach in Japan. MATERIALS AND METHODS Our analysis compared the 'EGFR testing strategy', in which EGFR mutation testing was performed before treatment and patients with EGFR mutations received gefitinib while those without mutations received standard… CONTINUE READING